Stay updated on Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page.

Latest updates to the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page
- CheckyesterdayChange DetectedA sitewide NIH notice about terminology changes during a website transition appears at the top of the study record.SummaryDifference0.8%

- Check8 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check15 days agoChange DetectedThe site footer revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check36 days agoChange DetectedCapitalization of the 'Find contact information' label was updated to 'Find Contact Information'. A new 'Revision: v3.7.0' entry was added to the history, indicating a new page version.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study record history now includes a new revision entry v3.6.6, replacing the previous v3.6.5 in the version list. This reflects an updated release note for the record.SummaryDifference0.1%

- Check78 days agoChange DetectedThe page’s revision label in the Record History updates from v3.6.4 to v3.6.5.SummaryDifference0.1%

Stay in the know with updates to Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page.